{
}
Big Pharma has increased its lobbying efforts in the 2024 election, with significant contributions flowing to both Democrats and Republicans. Notably, Harris has received nearly $1.7 million from the pharma sector, while Trump garnered just over $300,000. Companies like Eli Lilly and Amgen are actively engaging in political donations, with Amgen favoring Republicans, while Roche and AstraZeneca show a slight Republican lean but with declining contributions.
Oil prices fell sharply on Monday as Israel's recent strike on Iran did not disrupt energy supplies, alleviating geopolitical tensions in the Middle East. Meanwhile, the yen dropped significantly after Japan's ruling coalition lost its parliamentary majority, raising concerns about future rate hikes. In other news, Eli Lilly plans to launch its weight-loss drug, Mounjaro, in Hong Kong by year-end.
Egypt faces a critical insulin shortage amid rising diabetes rates, with NCDs accounting for 82% of deaths. Despite initiatives for local production, logistical and financial barriers persist, leaving many, especially in rural areas, struggling to access affordable diabetes care and supplies.
VHT and XLV are two prominent ETFs in the healthcare sector, with VHT managing $18.20 billion and XLV $41.08 billion in assets. VHT boasts a 1.39% yield and a strong performance, gaining 19.6% over the past year, while XLV offers a 1.50% yield and has risen 18.2% in the same period. Both funds have received an overall rating of A, indicating strong buy potential, with VHT ranked #2 and XLV ranked #1 among 42 ETFs in their category.
Novo Nordisk's diabetes drug Ozempic, containing semaglutide, may significantly lower the risk of developing Alzheimer’s disease by 40% to 70% compared to other diabetes medications, according to a recent study. This research highlights the potential of GLP-1 drugs to offer preventive benefits against the memory-robbing condition, which is projected to affect nearly 13 million Americans by 2050. Further clinical trials are needed to confirm these findings and explore the effects of GLP-1s in patients with obesity.
Novo Nordisk is seeking to restrict compounded versions of its weight-loss drugs, Ozempic and Wegovy, by lobbying the FDA to add semaglutide to its Demonstrable Difficulties for Compounding list, citing safety concerns. This move aims to protect patients and ensure they receive FDA-approved medications, as compounded versions are often sold at significantly lower prices. The compounding industry disputes these claims, arguing that the action is more about protecting profits than patient safety.
Novo Nordisk has requested the FDA to prohibit compounding pharmacies from producing unapproved versions of its diabetes and weight loss drugs, Ozempic and Wegovy, citing safety concerns due to the complexity of semaglutide. The company has also filed numerous lawsuits against clinics and pharmacies for similar reasons, as patients seek cheaper alternatives amid ongoing shortages of the branded medications. The FDA is currently reviewing Novo Nordisk's petition while warning about the risks associated with compounded semaglutide products.
Mangoceuticals, Inc. (NASDAQ: MGRX) is exploring strategic alternatives to enhance shareholder value, considering options like mergers and acquisitions. The company, specializing in telemedicine for men's health, faces challenges including cash consumption and a lawsuit from Eli Lilly over a weight loss drug. Despite a recent stock decline, MangoRx maintains a healthy gross profit margin and holds more cash than debt, positioning itself for potential partnerships.
Eli Lilly has filed lawsuits against three medical spas and online vendors for selling products claiming to contain tirzepatide, the active ingredient in its weight-loss drug Zepbound. The lawsuits, citing false advertising and safety risks, target Pivotal Peptides, MangoRx, and Genesis Lifestyle Medicine, with Lilly seeking court orders to halt their sales and unspecified monetary damages. The company emphasizes that these actions aim to protect consumers from misleading claims and untested formulations.
Novo Nordisk's oral diabetes drug Rybelsus has shown a 14% reduction in the risk of heart attacks, strokes, and cardiovascular death in a Phase 3 trial involving over 9,600 participants with diabetes and existing heart or kidney disease. The company plans to seek FDA approval by late 2024 to expand its use for heart health, joining other diabetes medications with similar benefits. Despite challenges in manufacturing semaglutide, Rybelsus has demonstrated potential for weight loss and cardiovascular protection.
Eli Lilly and Company
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
big pharma ramps up campaign contributions ahead of 2024 elections
United States Dollar
Eli Lilly and Company
ASTRAZENECA
Roche Art Sàrl
Amgen Inc.
Merck & Co., Inc.
GBR
CHE
USA
David Ricks
Brett Guthrie
Robert Bradway
Show more
08:11 28.10.2024
oil prices fall as geopolitical tensions ease and yen drops amid turmoil
04:11 28.10.2024
Egypt faces insulin access challenges amid rising diabetes rates and production delays
United States Dollar
Egyptian Pound
Eli Lilly and Company
EVA Pharma
EGY
Bente Mikkelsen
Khaled Abdel Ghaffar
Mohamed Shabeen
Riad Armanious
Show more
18:57 25.10.2024
healthcare etfs show strong performance and consistent dividend growth
Eli Lilly and Company
UnitedHealth Group Incorporated
Johnson & Johnson
AbbVie Inc.
USA
Rajkumari Saxena
Show more
23:30 24.10.2024
ozempic may lower alzheimer's risk in type 2 diabetes patients study finds
Alzheimer’s Association
Eli Lilly and Company
National Institutes OF Health Federal Credit Union CREDIT_UNION
Case Western Reserve University SCHOOL
Novo Nordisk A/S
DNK
USA
Rong Xu
Donald Trump
Joe Biden
Show more
13:00 24.10.2024
Novo Nordisk seeks to restrict compounded versions of semaglutide drugs
United States Dollar
Eli Lilly and Company
Novo Nordisk A/S
DNK
Scott Brunner
Jamie Bennett
Amanda Hils
Show more
16:27 23.10.2024
novo nordisk seeks fda ban on compounded versions of semaglutide
15:44 23.10.2024
Mangoceuticals explores strategic options to enhance shareholder value amid challenges
Eli Lilly and Company
Vipragen Biosciences
Platinum Point Capital
Mangoceuticals, Inc.
USA
Show more
14:35 22.10.2024
eli lilly files lawsuits against vendors for selling copycat weight loss drugs
23:47 21.10.2024
Novo diabetes pill Rybelsus shows heart health benefits in major trial
United States Dollar
Eli Lilly and Company
Boehringer Ingelheim KG
AstraZeneca PLC
Novo Nordisk A/S
DNK
Show more
18:11 21.10.2024
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Finance Mergers & Acquisitions
Retail and Consumer Goods
Global Financial Events
AI Innovations
Industry Mergers & Acquisitions
Banking Regulations
Startups & Entrepreneurship
Funding Rounds & Investments
Central Bank Actions
Market Analysis and Predictions
Supply Chain Management
CEO Changes
Global Trade Developments
Government Policies
AI & Automation Regulations
Inflation and Monetary Impact
Government Economic Policies
Countries:
Companies:
NVIDIA Corporation
Apple Inc.
Wells Fargo & Company
Huawei Technologies CO. Ltd.
The Goldman Sachs Group, Inc.
Tesla, Inc.
Barclays PLC
Bank of America Corporation
BNP Paribas SA
Citigroup Inc.
Microsoft Corporation
Morgan Stanley
Amazon.com, Inc.
HSBC HOLDINGS
Erste Group Bank AG
Berkshire Hathaway Inc.
American Express Co
DEUTSCHE TELEKOM
Banco Santander, S.A.
HSBC Holdings plc
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Indian Rupee
Chinese Yuan
Japanese Yen
United Arab Emirates Dirham
Offshore Chinese Yuan
Saudi Riyal
Australian Dollar
Hong Kong Dollar
Swedish Krona
Canadian Dollar
Brazilian Real
South Korean Won
Norwegian Krone
Egyptian Pound
Russian Ruble
Turkish Lira
People: